These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2004-004414-17 Ensayo clínico multicéntrico, prospectivo, abierto, no controlado para determinar la eficacia y seguridad de DepoCyte (citarabina liposómica inyectable) para el tratamiento de la recidiva de SNC en pa... not-yet-due
Ongoing 2005-000186-19 Estudio nacional, multicéntrico, abierto, de tratamiento de inducción con VELCADE y Dexametasona (VELCADEXA) en régimen alternante, previo a trasplante en pacientes menores de 65 años con mieloma múlt... not-yet-due
Ongoing 2005-000703-34 Ensayo Clínico de Tolerancia y Seguridad de Anfotericina B liposómica (AMBISOME) Nebulizada en la Profilaxis de la Aspergilosis Pulmonar Invasora en la Leucemia Mieloide Aguda (LMA) y en el Trasplante... not-yet-due
Ongoing 2005-001067-64 Multicentre study of optimization of therapy in mature B-cell acute lymphoblastic leukemia and Burkitt's lymphoma in adults (over 15 years) not-yet-due
Ongoing 2005-001110-41 Estudio Fase III Nacional, Abierto, Multicéntrico, Randomizado, Comparativo de VBMCP-VBAD/Velcade versus Talidomida/Dexametasona versus Velcade/Talidomida/Dexametasona como terapia de inducción seguid... not-yet-due
Completed, but no date 2005-001111-21 Estudio Fase III Nacional, Abierto, Multicéntrico, Randomizado, Comparativo de tratamiento de inducción con Melfalán/Prednisona/VelcadeÒ versus Talidomida/Prednisona/VelcadeÒ seguido de tratamiento de... bad-data
Ongoing 2005-002813-19 “Estudio en fase II, multicentrico, prospectivo, abierto, de tratamiento anticipado con valganciclovir de la infección por citomegalovirus en el transplante alogénico de progenitores hematopoyético ”. not-yet-due
Ongoing 2005-004973-55 ESTRATEGIA DE MANEJO ANTIFUNGICO DEL PACIENTE ONCOHEMATOLOGICO NEUTROPENICO. EMPLEO DE VORICONAZOL COMO TRATAMIENTO ANTICIPADO. not-yet-due
Ongoing 2006-000755-18 Estudio Fase IV, Nacional, Multicéntrico, competitivo, aleatorizado, doble ciego, controlado de grupos paralelos, para determinar la seguridad, tolerabilidad, y eficacia de aprepitant, más palonosetró... not-yet-due
Ongoing 2006-003750-23 Treatment With Dense Doses of Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immun... not-yet-due
Not reported Terminated 2007-000649-36 A phase III multicentre, randomized open-label study of Revlimid (lenalidomide) plus dexamethasone (ReDex) versus observation in patients with smoldering multiple myeloma (MM) at high risk of progress... 2018-09-04 due-trials
Ongoing 2007-000972-18 Estudio multicéntrico, no aleatorizado, abierto, para valorar la eficacia y la seguridad de la combinación de azacitidina y eritropoyetina beta en pacientes con síndromes mielodisplásicos (SMDs) depen... not-yet-due
Completed, but no date 2007-006601-25 Estudio abierto, multicéntrico, aleatorizado en fase II, para evaluar la eficacia de tratamiento tras la respuesta terapéutica inicial al régimen R-CHOP en pacientes con linfoma folicular no tratados ... bad-data
Not reported Terminated 2009-009422-92 Ensayo clínico multicéntrico, prospectivo, abierto y con control histórico para determinar la eficacia y seguridad de la administración de DepoCyte (citarabina liposómica inyectable) como profilaxis d... 2012-07-31 due-trials
Ongoing 2009-010827-23 Estudio nacuinal, multicéntrico, abierto, de tratamiento de inducción con VELCADE y Dexametasona en pacientes con mieloma múltiple e insuficiencia renal no tratados previamente not-yet-due
Completed, but no date Terminated 2009-011090-33 ESTUDIO PILOTO FASE II, MULTICÉNTRICO, NO ALEATORIZADO, PARA VALORAR LA EFICACIA Y LA SEGURIDAD DE LENALIDOMIDA EN INDUCCIÓN Y POST-INDUCCIÓN EN PACIENTES CON LEUCEMIA MIELOIDE AGUDA DE NOVO (LMA) CON... bad-data
Ongoing 2009-017440-13 EVALUACIÓN DEL EFECTO ANTITUMORAL DEL ÁCIDO ZOLEDRÓNICO EN PACIENTES CON MIELOMA MÚLTIPLE Y RECAÍDA BIOQUÍMICA ASINTOMÁTICA: ENSAYO CLÍNICO PROSPECTIVO DEL GRUPO GEM/PETHEMA not-yet-due
Completed, but no date 2009-017707-28 Ensayo multicéntrico, fase II de Lenalidomida, Ciclofosfamida y Dexametasona en pacientes con amiloidosis sistémica primaria (AL) de nuevo diagnóstico no candidatos a trasplante. bad-data
Ongoing 2010-018379-70 Estudio Fase IIb Nacional, Abierto, Multicéntrico, Randomizado, Comparativo de tratamiento con un esquema secuencial Melfalán/Prednisona/Bortezomib (Velcade®) (MPV) seguido de Lenalidomida (Revlimid®)... not-yet-due
Completed, but no date Terminated 2010-019718-25 Ensayo clínico multicéntrico, prospectivo, abierto, de un solo grupo, de fase II para analizar la terapia de inducción con una combinación de clofarabina y dosis bajas de citarabina seguido de terapia... bad-data
Reported results 2010-022855-46 AN OPEN LABEL PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INDUCTION AND CONSOLIDATION THERAPY WITH NILOTINIB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS AGED 55 YEARS AND OVER WITH PHILADEL... 2020-03-10 due-trials
Ongoing 2011-000293-62 Phase II, Open, National, Multicenter Study of Bendamustine, Bortezomib (Velcade) and prednisone (BVP) in patients with newly diagnosed multiple myeloma (BenVelPres) Estudio de Fase II Abierto, Nac... not-yet-due
Completed, but no date 2011-000971-15 Multicentric, prospective, open-label, of one group and phase I-II clinical trial to analyze induction treatment with a combination of fludarabine, idarubicin, cytarabine, G-CSF and plerixafor for the... bad-data
Ongoing 2012-004259-36 Multicenter, open-label, non-randomized Phase II trial of dasatinib in patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML) who meet criteria for late suboptimal response after prior imati... not-yet-due
Completed, but no date 2012-005683-10 Estudio fase III nacional, multicéntrico, abierto, aleatorizado, de tratamiento de inducción con bortezomib/lenalidomida/dexametasona (VRD-GEM), seguido de altas dosis de quimioterapia con melfalán-20... bad-data
Ongoing 2013-004323-37 Single nucleotide polymorphism association with response and toxic effects in patients with Ph+ CP-CML treated with bosutinib after relapse or intolerance to previous treatment. Estudio de correlac... not-yet-due
Reported results 2014-000319-15 A phase III, multicentre, randomized, open label clinical trial comparing azacytidine (Vidaza®) versus fludarabine plus cytarabine in elderly patients with newly diagnosed acute myeloid leukemia. E... 2019-10-28 due-trials
Not reported 2014-000554-10 A randomized, open-label, national multicenter, phase III trial studying maintenance treatment with lenalidomide and dexamethasone versus lenalidomide, dexamethasone and MLN9708 after autologous hemat... 2022-06-17 due-trials
Exempt Terminated 2014-002740-41 Phase I/II, Multicenter, Open Label, Clinical Trial of Filanesib (ARRY-520) in combination with Pomalidomide and Dexamethasone for relapsed/refractory MM patients Ensayo clínico de Fase I/II abiert... 2020-03-23 not-yet-due
Ongoing 2014-002948-40 A phase II multicenter study of carfilzomib, lenalidomide and dexamethasone (KRd) plus high-dose therapy with melphalan-200 and autologous stem cell transplantation, followed by consolidation with KRd... not-yet-due
Ongoing 2015-001151-68 A randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracycLines-based chemotherapy (AIDA regimen) for patient with newLy diagnose... not-yet-due
Ongoing 2015-001183-19 Lenalidomide and dexamethasone (Ld) versus Clarithromycin / Lenalidomide [Revlimid®] / Dexamethasone (BiRd) as initial therapy in Multiple Myeloma. Lenalidomida y dexametasona (Ld) versus Claritrom... not-yet-due
Not reported 2015-003359-23 Clinical Trial of Phase II, Open Label, Multicenter, of the monoclonal antibody anti-PD1 Pembrolizumab (MK-3475) as consolidation therapy in patients with multiple myeloma with residual disease after ... 2020-02-20 due-trials
Ongoing 2015-004202-41 CONCURRENT PONATINIB WITH CHEMOTHERAPY FOR YOUNG ADULTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA. PONATINIB Y QUIMIOTERAPIA EN ADULTOS JÓVENES CON LEUCEMIA... not-yet-due
Ongoing 2016-004877-42 A phase II, open-label study to evaluate the effect of blinatumomab administered during consolidation to reduce the level of minimal residual disease (MRD) assessed through flow cytometry in adult pat... not-yet-due
Ongoing 2016-004937-26 A multicenter, non-randomized, open label study to evaluate the efficacy and security of Ibrutinib followed by ofatumumab consolidation in previously untreated patients with Chronic Lymphocytic Leukem... not-yet-due
Ongoing 2016-005008-24 Carfilzomib and Dexamethasone in combination with Cyclophosphamide vs. Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: a phase II randomized controlled trial. C... not-yet-due
Ongoing 2017-000044-18 Induction therapy with bortezomib-melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) versus carfilzomib, lenalidomide and dexamethasone (KRd) plus/minus daratumumab, 18 cyc... not-yet-due
Ongoing 2017-002326-21 An Open-label, Multicenter, Phase 2 trial of selinexor (KPT-330), bortezomib and low-dose dexamethasone plus daratumumab (SELIBORDARA) for the treatment of patients with refractory or relapsed and ref... not-yet-due
Exempt Terminated 2017-004714-25 Phase I-II trial, open and nonrandomized, to assess the role of Idelalisib in patients with acute lymphoblastic leukemia (ALL) relapsed or refractory to other treatments, and in elderly patients with ... 2020-06-02 not-yet-due
Listed as ongoing, but also has a completion date 2018-002851-14 A 2:1 randomized phase II trial to compare the efficacy and safety of standard chemotherapy plus quizartinib versus standard chemotherapy plus placebo in adult patients with newly diagnosed FLT3 wild-... 2024-10-02 bad-data
Completed, but no date 2018-004353-24 A phase II, multicentre, open label clinical trial to assess the efficacy and toxicity of induction and consolidation with CPX-351 for patients aged 60 to 75 years with secondary or high-risk acute my... bad-data
Completed, report not yet due 2019-001323-12 A randomized phase III, multicentre, open label clinical trial comparing azacitidine plus pevonedistat versus azacitidine in Older/Unfit patients with newly diagnosed acute myeloid leukemia who are in... 2024-11-05 not-yet-due
Ongoing 2019-001804-39 Phase III Randomized Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Early Stage CLL With High Risk of Early Disease Progression Estudio fase III aleatorizado para i... not-yet-due
Exempt 2019-001976-12 A multicenter, prospective, non-randomized, Phase I-II trial to assess the efficacy and safety of the combination of oral quizartinib and the FLAG-IDA chemotherapy regimen in first relapsed/refractory... not-yet-due
Exempt 2020-000406-28 A phase I-II, multicentre, open label clinical trial to assess the safety and tolerability of the combination of low-dose cytarabine or azacitidine, plus Venetoclax and Quizartinib in newly diagnosed ... not-yet-due
Exempt 2021-002125-15 An open label, multicenter, phase I/II study of belantamab mafodotin in combination with Kd for the treatment of relapsed myeloma patients, refractory to lenalidomide Estudio de fase I/II, abierto ... not-yet-due
Ongoing 2021-002190-25 Multicenter, phase II, national and open-label study to evaluate Iberdomide-dexamethasone alone or in combination with standard MM treatment regimens in transplant ineligible newly diagnosed patients... not-yet-due
Ongoing 2021-004130-11 GEM21menos65. A Phase III trial for NDMM patients who are candidates for ASCT comparing Extended VRD plus Early Rescue Intervention vs Isatuximab-VRD vs Isatuximab-V-Iberdomide-D Ensayo de fase III... not-yet-due
Ongoing 2022-000598-15 An open label, multicenter, Phase 2, pilot study, evaluating early treatment with bispecific T-cell redirectors (teclistamab and talquetamab) in the front line therapy of newly diagnosed high -risk mu... not-yet-due